Close
x
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX Dec 07 2021 11:41
    57,629.90 +882.76 ( +1.56%)
  • NIFTY Dec 07 2021 11:49
    17,169.65 +257.40 ( +1.52%)
  • SENSEX Dec 07 2021 11:41
    57,629.90 +882.76 ( +1.56%)
  • NIFTY Dec 07 2021 11:49
    17,169.65 +257.40 ( +1.52%)
  • Nasdaq Dec 07 2021 04:30
    15,225.15 +139.68 ( +0.93%)
  • DJIA Dec 07 2021 04:30
    35,227.03 +646.95 ( +1.87%)
  • S&P 500 Dec 07 2021 04:30
    4,591.67 +53.24 ( +1.17%)
  • Hang Seng Dec 06 2021 02:10
    23,349.38 -417.31 (-1.76%)
  • Crude Oil Dec 07 2021 11:40
    5,323.00 +124.00 ( +2.39%)
  • Gold Dec 07 2021 11:40
    47,947.00 +33.00 ( +0.07%)
  • Silver Dec 07 2021 11:40
    61,641.00 +371.00 ( +0.61%)
  • Copper Dec 07 2021 11:40
    730.85 -3.25 (-0.44%)
  • Pound / Rupee Dec 23 2016 22:30
    99.31 -0.28 (-0.28%)
  • Dollar / Rupee Dec 23 2016 22:30
    75.06 +0.19 ( +0.25%)
  • Euro / Rupee Dec 23 2016 22:30
    84.87 +0.11 ( +0.13%)
  • Yen / Rupee Dec 23 2016 22:30
    0.67 0.00 ( +0.43%)

FDC Ltd

BSE Code : 531599 | NSE Symbol : FDC | ISIN:INE258B01022| SECTOR : Pharmaceuticals |

NSE BSE
 
SMC up arrow

280.20

0.40 (0.14%) Volume 280564

07-Dec-2021 11:39:53

Prev. Close

279.80

Open Price

280.00

Bid Price (QTY)

280.20(84)

Offer Price (QTY)

280.50(3)

 

Today’s High/Low 283.20 - 276.60

52 wk High/Low 404.90 - 255.20

Key Stats

MARKET CAP (RS CR) 4743.56
P/E 16.56
BOOK VALUE (RS) 112.5623401
DIV (%) 0
MARKET LOT 1
EPS (TTM) 16.97
PRICE/BOOK 2.49639444018631
DIV YIELD.(%) 0
FACE VALUE (RS) 1
DELIVERABLES (%) 54
4

News & Announcements

29-Nov-2021

FDC Ltd - FDC Limited - Analysts/Institutional Investor Meet/Con. Call Updates

22-Nov-2021

FDC Ltd - FDC Limited - Loss of Share Certificates

15-Nov-2021

FDC Ltd - FDC Limited - Press Release

13-Nov-2021

FDC consolidated net profit declines 17.83% in the September 2021 quarter

02-Nov-2021

FDC to announce Quarterly Result

08-Sep-2021

FDC schedules AGM

03-Aug-2021

FDC to announce Quarterly Result

12-Jul-2021

FDC launches India's first oral suspension of Favipiravir

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Alembic Ltd 506235 ALEMBICLTD
Alembic Pharmaceuticals Ltd 533573 APLLTD
Alkem Laboratories Ltd 539523 ALKEM
ANG Lifesciences India Ltd 540694
Anglo-French Drugs & Industries Ltd 40169
Anupam Rasayan India Ltd 543275 ANURAS
Astron Drugs & Industries Ltd 524206
Aurobindo Pharma Ltd 524804 AUROPHARMA
Bajaj Healthcare Ltd 539872 BAJAJHCARE
Bal Pharma Ltd 524824 BALPHARMA
Biocon Ltd 532523 BIOCON
Bombay Drugs & Pharma Ltd (Merged) 524512
Brooks Laboratories Ltd 533543 BROOKS
Cadila Healthcare Ltd 532321 CADILAHC
Cebon India Ltd 524272
Celestial Biolabs Ltd 532871 CELESTIAL
Cepham Organics Ltd 507756
Cian Healthcare Ltd 542678
Cipla Ltd 500087 CIPLA
Claris Lifesciences Ltd 533288
Concord Drugs Ltd 538965
Dee-Pharma Ltd 507722 DEEPHARMA
Dishman Carbogen Amcis Ltd 540701 DCAL
Dr Reddys Laboratories Ltd 500124 DRREDDY
Dr Sabharwals Manufacturing Labs Ltd 507743
Dr.Datsons Labs Ltd 533412 DRDATSONS
Druid Pharma Ltd 40430
Earum Pharmaceuticals Ltd 542724
Eupharma Laboratories Ltd 530409 EUPHARMLAB
Glenmark Life Sciences Ltd 543322 GLS
Glenmark Pharmaceuticals Ltd 532296 GLENMARK
Gufic BioSciences Ltd 509079 GUFICBIO
Hindustan Bio Sciences Ltd 532041
Hindustan Biotech Ltd 40162
Indoco Remedies Ltd 532612 INDOCO
Ind-Swift Laboratories Ltd 532305 INDSWFTLAB
IOL Chemicals & Pharmaceuticals Ltd 524164 IOLCP
Ipca Laboratories Ltd 524494 IPCALAB
J B Chemicals & Pharmaceuticals Ltd 506943 JBCHEPHARM
Jagsonpal Pharmaceuticals Ltd 507789 JAGSNPHARM
Jayant Vitamins Ltd 506518
Jupiter Bioscience Ltd 524826 JUPITER
KDL Biotech Ltd 532291 KOPDRUGS
Kopran Ltd 524280 KOPRAN
Kothari Phytochemicals & Industries Ltd 40136
Lasa Supergenerics Ltd 540702 LASA
Lupin Laboratories Ltd (Merged) 500258 LUPINLAB
Lyka Labs Ltd 500259 LYKALABS
Mangalam Drugs and Organics Ltd 532637 MANGALAM
Medico Remedies Ltd 540937
Mercury Phytochem Ltd 524498
Merind Ltd 506895 MARIND
Mesco Pharmaceuticals Ltd 500274 MESCOPHARM
Morepen Laboratories Ltd 500288 MOREPENLAB
Mylan Laboratories Ltd 524794 MATRIXLABS
Natco Pharma Ltd 524816 NATCOPHARM
Oriental Remedies & Herbals Ltd 526989
Ortin Laboratories Ltd 539287 ORTINLAB
P C I Chemicals & Pharmaceuticals Ltd 524792
Pan Drugs Ltd 531440
Panacea Biotec Ltd 531349 PANACEABIO
Parnax Lab Ltd 506128
Phaarmasia Ltd 523620
Pharmaceutical Products of India Ltd 524113 PPIL
Piramal Enterprises Ltd 500302 PEL
Ranbaxy Laboratories Ltd (Merged) 500359 RANBAXY
RPG Life Sciences Ltd 532983 RPGLIFE
Saamya Biotech (India) Ltd 532905
Sakar Healthcare Ltd 538377 SAKAR
Sandoz (India) Ltd (Merged) 531990
Sharda Drugs & Industries Ltd 24206
Shree Ganesh Biotech India Ltd 539470
Shree Ganesh Remedies Ltd 540737
Siddhartha Pharmachem Ltd 532122
SMS Lifesciences India Ltd 540679 SMSLIFE
Socrus Bio Sciences Ltd 524719
SOL Pharmaceuticals Ltd 500393 SOLPHARMA
Solara Active Pharma Sciences Ltd 541540 SOLARA
Source Natural Foods & Herbal Supplements Ltd 531398
Strides Pharma Science Ltd 532531 STAR
Sumitra Pharmaceutical & Chemicals Ltd (Merged) 524133 SUMITRAPHA
Sun Pharmaceuticals Industries Ltd 524715 SUNPHARMA
Supriya Pharmaceuticals Ltd 524784
Surya Pharmaceutical Ltd 532516 SURYAPHARM
Suven Pharmaceuticals Ltd 543064 SUVENPHAR
Syngene International Ltd 539268 SYNGENE
Syschem (India) Ltd 531173
Themis Medicare Ltd 530199 THEMISMED
Titan Biotech Ltd 524717
Tonira Pharma Ltd(merged) 530155
Torrent Pharmaceuticals Ltd 500420 TORNTPHARM
Triochem Products Ltd 512101
TTK Healthcare Ltd 507747 TTKHLTCARE
Unichem Laboratories Ltd 506690 UNICHEMLAB
Unicorn Pharmaceuticals (India) Ltd 524334
Valencia Nutrition Ltd 542910
Vardhaman Laboratories Ltd 524796
Vikram Thermo (India) Ltd 530477
Vineet Laboratories Ltd 543298 VINEETLAB
Vivimed Labs Ltd 532660 VIVIMEDLAB
Welcure Drugs & Pharmaceuticals Ltd 524661
Wintac Ltd 524758
Wockhardt Ltd 532300 WOCKPHARMA
Zillion Pharmachem Ltd 524476 ZILONPHARM
Zota Health Care Ltd 538426 ZOTA

Share Holding

Category No. of shares Percentage
Total Foreign 9360347 5.55
Total Institutions 7854697 4.65
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 4928843 2.92
Total Promoters 117077658 69.36
Total Public & others 29588539 17.53
Total 168810084 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About FDC Ltd

FDC Limited is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). FDC's formulation department designs and develops products for various global markets and the highly regulated markets of US and Europe. The company has built a visible presence in the Regulated and Emerging markets. Promoted as a partnership firm in 1936 by the late Anand Chandravarkar to import pharmaceutical dosage forms, specialised infant foods and surgical goods Fairdeal Corporation (P) Ltd, as the company was known, was converted into a private limited company in September 23rd, 1940. It set up a formulation unit at Jogeshwari, Bombay in 1949. FDC has 2 wholly owned subsidiaries namely FDC Inc., USA and FDC International Ltd, UK and 1 Joint Venture business, namely Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. at South Africa as on 31 March 2019. FDC manufactures Electral, oral rehydration salt (ORS), being a leader in this segment. FDC manufactures bulk drugs, formulations and food products. The plant at Roha manufactures pharma dosage forms, food products and bulk drugs for the anti-rheumatic, anti-asthmatic, opthalmic and ENT segments. The company part financed its technical upgradation/modernisation/backward integration/expansion plans from the proceeds of its initial public issue in Jan.'96. The company set up a modern manufacturing plant at Goa for manufacture of tablet dosage forms. The plant has commenced commercial production in Sep 2000. The plant is designed to meet UK/US standards on solid dosage form. In Feb. 2001, the company has signed a marketing tie-updeal with Aspen Pharmacare of South Africa. Through this alliance, FDC will be initially marketing 10-12 ophthalmic products manufactured at its plants in India and approved by the UK Medicines Control Agency in South Africa. FDC will also enter into a licensing arrangement with Aspen Pharmacare for solid dosage forms and oral rehydration salts, to be manufactured locally in South Africa at Aspen's facilities with knowhow from FDC. Aspen Pharmacare is the largest listed pharmaceutical company in South Africa and a dominant player in generic medicine. The total market for ophthalmic products in South Africa is estimated at Rs 78.70 cr, and FDC hopes to achieve a 30% marketshare in five years. During 2000-01, the company's Roha plant, manufacturing basic raw materials, was inspected and approved by US FDA. The company is also setting up a modern manufacturing plant at a separate site in Goa. The plant will be a world class facilities with quality systems of International GMP Standards and it will also enable the company to enter into US market. The trial runs and commerical production is expected to be commenced in March 2004. To tap the Sub Sahara African countries FDC is planning to set up a marketing joint venture in South Africa and Russia. FDC is setting up a manufacturing facility at Baddi, Himachal Pradesh, for the manufacturing of Cephalosporin drugs. This facility is expected to be operational in 2006. The company has received approvel from US FDA for its sterile manufacturing facility for ophthamlmic dosage forms at Waluj, Aurangabad and an analytical research and devrelopment laboratory at Jogeshwari, Mumbai. Also the company is setting up an additional facility at Waluj by adding one more Form-Fill-Seal (FFS) machine during the year 2004-05. During the year 2004-2005, FDC has received a certification for its plant at Waluj conforms to the Quality Management System Standards ISO 9001:2000 and ISO13485: 2003 respectively. This will enable the company to enhance its exports to European countries. In the year 2004-05, the company has issued bonus equity shares in the ratio of 1:1. In 2006, The company has expanded its installed capacity of Basic Drugs, Capsules and Formulations (Cream, Powder, Ointments etc.) by 2350 kgs, 20,00,000 nos and 1342200 kgs respectively during the year. With this expansion the total capacity of Basic Drugs, Capsules and Formulations (Cream, Powder, Ointments, etc) has been increased to 119050 kgs, 19.20 nos in crores and 77,77,920 respectively. The company has set up a production facility at Baddi, Himachalpradesh, the production at this new site will commence from July 2006. FDC concluded buyback of its fully paid-up equity shares of Re.1 each, on August 16, 2013. During the buyback period, the company bought back 5,087,343 equity shares of Re.1 each and the total outlay for the buyback was Rs. 4,651.17 lacs. All the equity shares bought back in the buyback offer were extinguished as on August 31, 2013. During the year ended 31 March 2014, FDC's newly introduced Calcium-Phosphorus Supplement, Calyumm-P suspension was launched at Paediatricians with much aplomb. Calyumm-P with its unique name & yummy flavour was well accepted and appreciated and was able to garner a good prescriber base at Paediatricians in the very first year of its launch. During the year under review, FDC got approval from European regulatory agencies for two generics products. A number of products were developed for registration in CIS, African countries and ROW. With regard to the Nutraceuticals business, FDC has successfully completed HACCP Recertification Audit and ISO22000: 2005 Surveillance audit for Roha plant. 2014-15 was the year for FDC, wherein the new divisional structure was put into effect. The new structure was created not only to give a focused approach to few of mega brands of the company, but also to ensure that FDC's presence is felt across different therapy areas (build newer Therapy Areas (TA)) where it has a presence. By doing so, FDC has also ensured that it is aligned to the right TA's from a long term perspective. FDC now operates through 7 marketing divisions including 2 new specialty divisions namely Dilse and Pixel. The Dilse Division is a canopied basket of Cardiovascular and Anti-diabetic products of FDC. The Pixel Division is launched with a view to reaching 12,200 numbers of Top Ophthalmologists. Overall, FDC product basket covers 14 therapeutic segments with a strong brand portfolio. FDC's balanced energy drink namely 'ENERZAL' became the drink provider for the Mumbai Marathon 2015. In Nutraceuticals business, FDC launched 'Enerzal' in Jar (Orange and Lime Flavour) during the year ended 31 March 2015. With regard to the license technology agreement signed by FDC for of recombinant Granulocyte Colony Stimulating Factor project, the company has successfully completed the Pre-clinical Trials and received permission from the Department of Biotechnology, to approach Drug Controller General of India (DCGI), for approval to conduct appropriate phase of Human Clinical Trials. On the Formulations business front, in addition to the European markets, FDC has grown its business in Australia in the financial year 2014-2015.In Nutraceuticals business, FDC launched 'Enerzal' in Pet Bottle (Orange and Apple Flavour) during the year ended 31 March 2016. With regards to recombinant Granulocyte Colony Stimulating Factor project, FDC has modified the existing manufacturing facility at Jogeshwari to suit the cGMP requirement to manufacture recombinant protein for clinical trial. Area qualification of this new R&D Biotechnology process area was completed successfully. With reference to FDC's project on the development of third generation thrombolyte, the company has approached an external party for process development and validation of the said thrombolyte molecule at downstream level and its subsequent technology transfer to FDC. Trial batches have been initiated at FDC and the Cell harvest shall be handed over to external party for development and validation of the purification strategy. FDC purchased the immovable property, which was occupied by the company as a lessee, from the lessors i.e. Ghaswalas, admeasuring 8,664 square meters located at 142-48, Swami Vivekananda Road, Jogeshwari (West), Mumbai for a total consideration of Rs. 261 crore during the financial year 2015-2016.The Scheme of Amalgamation of Anand Synthochem Limited (a wholly owned subsidiary), Soven Trading and Investment Company Private Limited, Sudipta Trading and Investment Company Private Limited and Transgene Trading and Investment Company Private Limited (Transferor Companies) and FDC Limited (Transferee Company) and their respective shareholders (the Scheme), which was approved by the Board on September 6, 2014 and the members at court convened meeting held on June 13, 2015 and public shareholders through Postal Ballot and e-voting on June 15, 2015 was sanctioned by the Bombay High Court on September 4, 2015. The Scheme has become effective on September 4, 2015 with appointed date being September 1, 2014. Accordingly, the Transferor Companies stand merged with the Transferee Company and the merger has been given effect to, in the financial statements of FDC Limited for the year ended March 31, 2016. Consequently, 55,385,000 equity shares of face value Re. 1 each held by the Transferor Companies in the Transferee Company has been cancelled and the Transferee Company has allotted 55,385,000 equity shares of face value of Re.1 each, credited as fully paid up, to the shareholders of Transferor Companies in accordance with the fair share entitlement ratio specified in the Scheme. During the year ended 31 March 2017, FDC launched various products in the market such as Ten DC & Ten DCM, Vitcofol Hb, Zocon KZ Shampoo, etc. The company has also aligned itself in terms of portfolios & priorities, in order to maintain its finest performance. In Nutraceuticals business, FDC launched the Enerzal 500 ml in pet bottle as well as 1 Litre in Tetrapak with Orange and Apple flavor during the year ended 31 March 2017. With regards to recombinant Granulocyte Colony Stimulating Factor project, inspection was conducted by Central Drugs Standard Control Organisation (CDSCO) along with Local Food, Drug and Authority (FDA) in consideration to FDC's application to grant No-objection Certificate for manufacturing the clinical grade material. With reference to FDC's project on the development of Third Generation Thrombolyte, it has obtained the Test License from Local FDA. The Board of Directors of FDC Limited in their meeting held on February 7, 2018 had given their approval for Buy Back of the company's fully paid-up equity shares of Re. 1 each from the Tender offer through Stock Exchange route, of upto 3,430,000 fully paid up equity shares of face value of Re. 1 each of the company at a price of Rs. 350/- per Share payable in cash for an aggregate Buyback consideration not exceeding Rs. 120.05 crore excluding transaction cost, viz. brokerage, applicable taxes such as securities transaction tax, service tax, stamp duty, etc., cost for the intermediaries appointed for the buyback and other incidental costs. The company completed the extinguishment of 3,430,000 Equity Shares comprising of (i) 3,429,951 Equity Shares in dematerialized form on March 28, 2018 and (ii) 49 equity shares in physical form on March 29, 2018 which were accepted pursuant to the aforesaid Buyback. During the year ended 31 March 2018, FDC has shifted to alternative formulae for brands falling under DCGI ban. Further the company has selectively launched the molecules viz. Itraconazole (Oral Antifungal) Brand Zitran, Luliconazole (Topical Antifungal) Brand Zocon L, Apremilast (Psoriatic arthritis) Brand Aprotyl, Cranberry extract + D Mannose (UTI infections) - Brand AV UTI. With regard to G-CSF project, the company has received the CDSCO Audit report on steps to be undertaken for grant of Non Objection certificate (NOC) to manufacture clinical grade material for human trials as required under Form 29. With reference to the company's project on the development of Third Generation Thrombolyte, the company has obtained a refolding and purification strategy from the external party. With reference to the company's project on the New Chemical entity, FDC has been successful in formulating the insoluble active molecule (TNF-04) for topical application and preliminary study is in progress for determining the efficacy of the molecule in animal model. On the Active Pharmaceutical Ingredients business front, FDC has filed USDMF for Telmisartan and Cinnarizine and has received CEP Certifications for Dorzolamide Hydrochloride and Salbutamol Sulfate. The company was audited by EDQM and has received EU GMP Certification for the product Bromhexine Hydrochloride Active Pharmaceutical Ingredients. As on 31 March 2019, the Company has 2 (Two) wholly owned Subsidiaries namely FDC Inc., USAand FDC International Ltd, UK and 1 (One) Joint Venture business, namely Fair Deal Corporation Pharmaceutical SA(Pty) Ltd. at South Africa. The Board of Directors of the company in their meeting held on May 24, 2019 had given their approval for Buy Back of the Company's fully paid-up equity shares of Re. 1/- each from the Tender offer through Stock Exchange route, of upto 3,430,000 (Thirty Four Lakhs Thirty Thousand only) fully paid up equity shares of face value of Re. 1/- each of the Company at a price of Rs. 350/- (Rupees Three Hundred Fifty only) per Share payable in Cash for an aggregate Buyback consideration not exceeding Rs. 120.05 Crore. The buy-back of equity shares through the stock exchange commenced on June 07, 2019 and was completed on July 23, 2019 and the Company bought back and extinguished a total of 3,430,000 equity shares at a price of Rs. 350/- per equity share. The Company acted promptly to mitigate the impact of COVID-19 pandemic and the ensuing nationwide lockdown. The Board of directors, at its meeting held on August 07, 2020 have approved a proposal of the Company to buy-back its 21,63,000 fully paid-up equity shares at a price of Rs.450 per equity shares from all the eligible equity shareholders of the Company on proportionate basis through the 'Tender offer' route in accordance with SEBI(Buy-Back of securities) Regulation, 2018. The Buyback of equity shares through the stock exchange commenced on September 16, 2020 and was completed on September 29, 2020 and the Company bought back and extinguished a total of 21,63,000 equity shares at a price of Rs. 450 per equity share on October 15, 2020. The Company had entered into definitive agreements for the acquisition of additional stake in Fair Deal Corporation pharmaceutical SA (PTY) Ltd., South Africa (FDC SA') throughsecondary acquisition of 143,000 equity shares of FDC SA, having Face value of RAND 1 each, and representing 44% of the share capital of FDC SA from Pharma Q Holdings Pty Ltd, one of the joint venture partner. The various closing conditions and applicable compliance had been duly completed and FDC SA has became subsidiary of the Company by holding 93% of equity share capital of FDC SA.

FDC Ltd Chairman Speech

FDC Ltd Company History

FDC Limited is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). FDC's formulation department designs and develops products for various global markets and the highly regulated markets of US and Europe. The company has built a visible presence in the Regulated and Emerging markets. Promoted as a partnership firm in 1936 by the late Anand Chandravarkar to import pharmaceutical dosage forms, specialised infant foods and surgical goods Fairdeal Corporation (P) Ltd, as the company was known, was converted into a private limited company in September 23rd, 1940. It set up a formulation unit at Jogeshwari, Bombay in 1949. FDC has 2 wholly owned subsidiaries namely FDC Inc., USA and FDC International Ltd, UK and 1 Joint Venture business, namely Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. at South Africa as on 31 March 2019. FDC manufactures Electral, oral rehydration salt (ORS), being a leader in this segment. FDC manufactures bulk drugs, formulations and food products. The plant at Roha manufactures pharma dosage forms, food products and bulk drugs for the anti-rheumatic, anti-asthmatic, opthalmic and ENT segments. The company part financed its technical upgradation/modernisation/backward integration/expansion plans from the proceeds of its initial public issue in Jan.'96. The company set up a modern manufacturing plant at Goa for manufacture of tablet dosage forms. The plant has commenced commercial production in Sep 2000. The plant is designed to meet UK/US standards on solid dosage form. In Feb. 2001, the company has signed a marketing tie-updeal with Aspen Pharmacare of South Africa. Through this alliance, FDC will be initially marketing 10-12 ophthalmic products manufactured at its plants in India and approved by the UK Medicines Control Agency in South Africa. FDC will also enter into a licensing arrangement with Aspen Pharmacare for solid dosage forms and oral rehydration salts, to be manufactured locally in South Africa at Aspen's facilities with knowhow from FDC. Aspen Pharmacare is the largest listed pharmaceutical company in South Africa and a dominant player in generic medicine. The total market for ophthalmic products in South Africa is estimated at Rs 78.70 cr, and FDC hopes to achieve a 30% marketshare in five years. During 2000-01, the company's Roha plant, manufacturing basic raw materials, was inspected and approved by US FDA. The company is also setting up a modern manufacturing plant at a separate site in Goa. The plant will be a world class facilities with quality systems of International GMP Standards and it will also enable the company to enter into US market. The trial runs and commerical production is expected to be commenced in March 2004. To tap the Sub Sahara African countries FDC is planning to set up a marketing joint venture in South Africa and Russia. FDC is setting up a manufacturing facility at Baddi, Himachal Pradesh, for the manufacturing of Cephalosporin drugs. This facility is expected to be operational in 2006. The company has received approvel from US FDA for its sterile manufacturing facility for ophthamlmic dosage forms at Waluj, Aurangabad and an analytical research and devrelopment laboratory at Jogeshwari, Mumbai. Also the company is setting up an additional facility at Waluj by adding one more Form-Fill-Seal (FFS) machine during the year 2004-05. During the year 2004-2005, FDC has received a certification for its plant at Waluj conforms to the Quality Management System Standards ISO 9001:2000 and ISO13485: 2003 respectively. This will enable the company to enhance its exports to European countries. In the year 2004-05, the company has issued bonus equity shares in the ratio of 1:1. In 2006, The company has expanded its installed capacity of Basic Drugs, Capsules and Formulations (Cream, Powder, Ointments etc.) by 2350 kgs, 20,00,000 nos and 1342200 kgs respectively during the year. With this expansion the total capacity of Basic Drugs, Capsules and Formulations (Cream, Powder, Ointments, etc) has been increased to 119050 kgs, 19.20 nos in crores and 77,77,920 respectively. The company has set up a production facility at Baddi, Himachalpradesh, the production at this new site will commence from July 2006. FDC concluded buyback of its fully paid-up equity shares of Re.1 each, on August 16, 2013. During the buyback period, the company bought back 5,087,343 equity shares of Re.1 each and the total outlay for the buyback was Rs. 4,651.17 lacs. All the equity shares bought back in the buyback offer were extinguished as on August 31, 2013. During the year ended 31 March 2014, FDC's newly introduced Calcium-Phosphorus Supplement, Calyumm-P suspension was launched at Paediatricians with much aplomb. Calyumm-P with its unique name & yummy flavour was well accepted and appreciated and was able to garner a good prescriber base at Paediatricians in the very first year of its launch. During the year under review, FDC got approval from European regulatory agencies for two generics products. A number of products were developed for registration in CIS, African countries and ROW. With regard to the Nutraceuticals business, FDC has successfully completed HACCP Recertification Audit and ISO22000: 2005 Surveillance audit for Roha plant. 2014-15 was the year for FDC, wherein the new divisional structure was put into effect. The new structure was created not only to give a focused approach to few of mega brands of the company, but also to ensure that FDC's presence is felt across different therapy areas (build newer Therapy Areas (TA)) where it has a presence. By doing so, FDC has also ensured that it is aligned to the right TA's from a long term perspective. FDC now operates through 7 marketing divisions including 2 new specialty divisions namely Dilse and Pixel. The Dilse Division is a canopied basket of Cardiovascular and Anti-diabetic products of FDC. The Pixel Division is launched with a view to reaching 12,200 numbers of Top Ophthalmologists. Overall, FDC product basket covers 14 therapeutic segments with a strong brand portfolio. FDC's balanced energy drink namely 'ENERZAL' became the drink provider for the Mumbai Marathon 2015. In Nutraceuticals business, FDC launched 'Enerzal' in Jar (Orange and Lime Flavour) during the year ended 31 March 2015. With regard to the license technology agreement signed by FDC for of recombinant Granulocyte Colony Stimulating Factor project, the company has successfully completed the Pre-clinical Trials and received permission from the Department of Biotechnology, to approach Drug Controller General of India (DCGI), for approval to conduct appropriate phase of Human Clinical Trials. On the Formulations business front, in addition to the European markets, FDC has grown its business in Australia in the financial year 2014-2015.In Nutraceuticals business, FDC launched 'Enerzal' in Pet Bottle (Orange and Apple Flavour) during the year ended 31 March 2016. With regards to recombinant Granulocyte Colony Stimulating Factor project, FDC has modified the existing manufacturing facility at Jogeshwari to suit the cGMP requirement to manufacture recombinant protein for clinical trial. Area qualification of this new R&D Biotechnology process area was completed successfully. With reference to FDC's project on the development of third generation thrombolyte, the company has approached an external party for process development and validation of the said thrombolyte molecule at downstream level and its subsequent technology transfer to FDC. Trial batches have been initiated at FDC and the Cell harvest shall be handed over to external party for development and validation of the purification strategy. FDC purchased the immovable property, which was occupied by the company as a lessee, from the lessors i.e. Ghaswalas, admeasuring 8,664 square meters located at 142-48, Swami Vivekananda Road, Jogeshwari (West), Mumbai for a total consideration of Rs. 261 crore during the financial year 2015-2016.The Scheme of Amalgamation of Anand Synthochem Limited (a wholly owned subsidiary), Soven Trading and Investment Company Private Limited, Sudipta Trading and Investment Company Private Limited and Transgene Trading and Investment Company Private Limited (Transferor Companies) and FDC Limited (Transferee Company) and their respective shareholders (the Scheme), which was approved by the Board on September 6, 2014 and the members at court convened meeting held on June 13, 2015 and public shareholders through Postal Ballot and e-voting on June 15, 2015 was sanctioned by the Bombay High Court on September 4, 2015. The Scheme has become effective on September 4, 2015 with appointed date being September 1, 2014. Accordingly, the Transferor Companies stand merged with the Transferee Company and the merger has been given effect to, in the financial statements of FDC Limited for the year ended March 31, 2016. Consequently, 55,385,000 equity shares of face value Re. 1 each held by the Transferor Companies in the Transferee Company has been cancelled and the Transferee Company has allotted 55,385,000 equity shares of face value of Re.1 each, credited as fully paid up, to the shareholders of Transferor Companies in accordance with the fair share entitlement ratio specified in the Scheme. During the year ended 31 March 2017, FDC launched various products in the market such as Ten DC & Ten DCM, Vitcofol Hb, Zocon KZ Shampoo, etc. The company has also aligned itself in terms of portfolios & priorities, in order to maintain its finest performance. In Nutraceuticals business, FDC launched the Enerzal 500 ml in pet bottle as well as 1 Litre in Tetrapak with Orange and Apple flavor during the year ended 31 March 2017. With regards to recombinant Granulocyte Colony Stimulating Factor project, inspection was conducted by Central Drugs Standard Control Organisation (CDSCO) along with Local Food, Drug and Authority (FDA) in consideration to FDC's application to grant No-objection Certificate for manufacturing the clinical grade material. With reference to FDC's project on the development of Third Generation Thrombolyte, it has obtained the Test License from Local FDA. The Board of Directors of FDC Limited in their meeting held on February 7, 2018 had given their approval for Buy Back of the company's fully paid-up equity shares of Re. 1 each from the Tender offer through Stock Exchange route, of upto 3,430,000 fully paid up equity shares of face value of Re. 1 each of the company at a price of Rs. 350/- per Share payable in cash for an aggregate Buyback consideration not exceeding Rs. 120.05 crore excluding transaction cost, viz. brokerage, applicable taxes such as securities transaction tax, service tax, stamp duty, etc., cost for the intermediaries appointed for the buyback and other incidental costs. The company completed the extinguishment of 3,430,000 Equity Shares comprising of (i) 3,429,951 Equity Shares in dematerialized form on March 28, 2018 and (ii) 49 equity shares in physical form on March 29, 2018 which were accepted pursuant to the aforesaid Buyback. During the year ended 31 March 2018, FDC has shifted to alternative formulae for brands falling under DCGI ban. Further the company has selectively launched the molecules viz. Itraconazole (Oral Antifungal) Brand Zitran, Luliconazole (Topical Antifungal) Brand Zocon L, Apremilast (Psoriatic arthritis) Brand Aprotyl, Cranberry extract + D Mannose (UTI infections) - Brand AV UTI. With regard to G-CSF project, the company has received the CDSCO Audit report on steps to be undertaken for grant of Non Objection certificate (NOC) to manufacture clinical grade material for human trials as required under Form 29. With reference to the company's project on the development of Third Generation Thrombolyte, the company has obtained a refolding and purification strategy from the external party. With reference to the company's project on the New Chemical entity, FDC has been successful in formulating the insoluble active molecule (TNF-04) for topical application and preliminary study is in progress for determining the efficacy of the molecule in animal model. On the Active Pharmaceutical Ingredients business front, FDC has filed USDMF for Telmisartan and Cinnarizine and has received CEP Certifications for Dorzolamide Hydrochloride and Salbutamol Sulfate. The company was audited by EDQM and has received EU GMP Certification for the product Bromhexine Hydrochloride Active Pharmaceutical Ingredients. As on 31 March 2019, the Company has 2 (Two) wholly owned Subsidiaries namely FDC Inc., USAand FDC International Ltd, UK and 1 (One) Joint Venture business, namely Fair Deal Corporation Pharmaceutical SA(Pty) Ltd. at South Africa. The Board of Directors of the company in their meeting held on May 24, 2019 had given their approval for Buy Back of the Company's fully paid-up equity shares of Re. 1/- each from the Tender offer through Stock Exchange route, of upto 3,430,000 (Thirty Four Lakhs Thirty Thousand only) fully paid up equity shares of face value of Re. 1/- each of the Company at a price of Rs. 350/- (Rupees Three Hundred Fifty only) per Share payable in Cash for an aggregate Buyback consideration not exceeding Rs. 120.05 Crore. The buy-back of equity shares through the stock exchange commenced on June 07, 2019 and was completed on July 23, 2019 and the Company bought back and extinguished a total of 3,430,000 equity shares at a price of Rs. 350/- per equity share. The Company acted promptly to mitigate the impact of COVID-19 pandemic and the ensuing nationwide lockdown. The Board of directors, at its meeting held on August 07, 2020 have approved a proposal of the Company to buy-back its 21,63,000 fully paid-up equity shares at a price of Rs.450 per equity shares from all the eligible equity shareholders of the Company on proportionate basis through the 'Tender offer' route in accordance with SEBI(Buy-Back of securities) Regulation, 2018. The Buyback of equity shares through the stock exchange commenced on September 16, 2020 and was completed on September 29, 2020 and the Company bought back and extinguished a total of 21,63,000 equity shares at a price of Rs. 450 per equity share on October 15, 2020. The Company had entered into definitive agreements for the acquisition of additional stake in Fair Deal Corporation pharmaceutical SA (PTY) Ltd., South Africa (FDC SA') throughsecondary acquisition of 143,000 equity shares of FDC SA, having Face value of RAND 1 each, and representing 44% of the share capital of FDC SA from Pharma Q Holdings Pty Ltd, one of the joint venture partner. The various closing conditions and applicable compliance had been duly completed and FDC SA has became subsidiary of the Company by holding 93% of equity share capital of FDC SA.

FDC Ltd Directors Reports

To,

The Members,

Your Directors have pleasure in presenting the 79th Annual Report together with the Audited Accounts for the year ended March 31,2019.

1. STANDALONE FINANCIAL RESULTS

(Rupees in lakhs)

Particulars 2018-2019 2017-2018
Revenue from operations (Net) 1,07,587.40 1,07,021.23
Other income 5,479.98 5,124.75
Total Income 1,13,067.38 1,12,145.98
Profit (before finance costs and depreciation /amortisation) 27,483.97 27,034.83
Finance costs 143.19 140.26
Depreciation and amortisation 3,313.77 3,503.90
Profit Before Exceptional items and Tax 24,027.01 23,390.67
Less: Exceptional items 397.11 -
Profit before tax 23,629.90 23,390.67
Less: Taxation
- Current Tax 6,660.00 6,780.00
- Deferred Tax (183.73) (220.74)
Profit After Tax 17,153.63 16,831.41
Other Comprehensive Income/(Loss) for the year (89.13) (27.61)
Total Comprehensive Income/(Loss) for the year 17,064.50 16,803.80
Earnings per equity share
(Basic & Diluted)
(Face value Re.1) 9.84 9.47

3. DIVIDEND

The Board of Directors of your Company, after considering relevant circumstances in Pharmaceutical industry and keeping in view the Company's Dividend Distribution Policy, has decided that it would be prudent, not to recommend any dividend for the year under review. As per Regulation 43A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, "Listing Regulations", the Company has formulated a Dividend Distribution Policy which is annexed as "Annexure A" and is also uploaded on the website of the Company i.e. www.fdcindia.com .

4. SHARE CAPITAL

During the year under review, the paid up Equity Share Capital of the Company as on March 31, 2019 is as follows:

Subscribed and Paid-up share capital March 31, 2019 March 31, 2018
174,403,084 (Previous year- 174,403,084) Equity shares of Re. 1 each, fully paid-up 174,403,084 174,403,084
Add: 3,145,000 (Previous year - 3,145,000) Equity shares forfeited 786,250 786,250
Total 175,189,334 175,189,334

Cancellation of Equity Shares Forfeited by the Company

In the past, the Board had forfeited 314,900./- shares of face value of Rs. 10/- each due to non-payment of call money of Rs. 7.5/- each by the shareholders, out of which forfeiture of 400 shares was annulled afterwards on receipt of call money.

After split of the shares in the year 2002, at present there are 3,145,000 forfeited shares of Rs. 0.25/- each containing total amount of Rs. 786,250 of forfeited capital.

While showing details of the equity share capital in the Balance sheet, the details of forfeited shares also needs to be shown till the time these shares are either re-issued or cancelled. Considering very small quantum of the shares, it is proposed to cancel these shares.

The Company decides not to reissue the forfeited shares of the Company. In such a case, the Board will cancel the forfeited shares and transfer the amount received on such shares to capital reserve account or other such accounts as per the applicable provisions of Indian Accounting Standards and Companies Act, 2013, "Act".

5. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

The management of your company presents the analysis of performance of the Company for the financial year ended March 31,2019 and its outlook for the future. This outlook is based on assessment of the current business environment. It may vary due to future economic and other developments, both in India and abroad.

A. Economic Overview:

When we met year ago economic activity was accelerating in almost all regions of the world and the global economy was projected to grow at 3.9 % in 2018 - 2019. One year later, much has changed: the escalation of US-China trade tensions, macroeconomic stress in Argentina and Turkey, disruptions to the auto sector in Germany, tighter credit policies in China, and financial tightening alongside the normalization of monetary policy in the larger advanced economies have all contributed to a significantly weakened global expansion, especially in the second half of 2018. With this weakness persist into 2019, the World Economic Outlook (WEO) projects a decline in growth in 2019 for 70 % of the global economy. Global growth, which peaked at close to 4 % in 2017, softened to 3.6 % in 2018, and is projected to decline further to 3.3 % in 2019.

(Source: IMF March, 2019)

India continues to be among the few growth economies, growth is projected to pick up to 7.3 % in 2019 and 7.5 % in 2020, supported by the continued recovery of investment and robust consumption amid a more expansionary stance of monetary policy and some expected impetus from fiscal policy. Growth in India is expected to stabilize at just under 7.75 % over the medium term, based on continued implementation of structural reforms and easing of infrastructure bottlenecks.

In India, continued implementation of structural and financial sector reforms with efforts to reduce public debt remain essential to secure the economy's growth prospects. In the near term, continued fiscal consolidation is needed to bring down India's elevated public debt. This should be supported by strengthening Goods and Services Tax compliance and further reducing subsidies. Important steps have been taken to strengthen financial sector balance sheets, including through accelerated resolution of non-performing assets under a simplified bankruptcy framework. These efforts should be reinforced by enhancing governance of public sector banks. Reforms to hiring and dismissal regulations would help incentivize job creation and absorb the country's large demographic dividend; efforts should also be enhanced on land reform to facilitate and expedite infrastructure development.

The Indian Pharmaceutical industry continues to enjoy structural advantages which maintains global competitiveness and fuels industry growth.

Cost Efficiency: Low cost of production and R&D boosts efficiency of Indian pharma companies, leading to competitive exports. Indian pharma exports reached US $ 17.15 billion in FY19. India's cost of production is approximately 33 % lower than that of the US. India's ability to manufacture high quality, low priced medicines, presents a huge business opportunity for the domestic industry.

Economic Drivers: Increasing penetration of health insurance to drive expenditure on medicine. With increasing penetration of pharmacies, especially in rural India, OTC drugs will be readily available.

Increasing Investments: Increasing private sector investments in R&D and acquisitions are driving the sector's growth. In FY18, Indian pharma companies invested 8.8 % of their sales in R&D. Between 2008-18; the S&P BSE Healthcare Index has grown at 16.72 %. In 2017, Indian pharmaceutical sector witnessed 46 Merger & Acquisition (M&A) deals worth US$ 1.47 billion.

Policy Support: Pharma Vision 2020 aimed at making India a global leader in end-to-end drug manufacturing. Under Budget 2019-20, allocation to the Ministry of Health and Family Welfare increased by 13.1 % to Rs. 61,398 crore (US$ 8.98 billion). In this sector, 100 % FDI is allowed under automatic route.

(Source: PwC, McKinsey, Pharmaceuticals Promotion Council of India)

B. Industry Structure & development:

As per AIOCD-AWACS Report, the Indian Pharma market grew by 9.6% in 2018-19, the Total Sales reported where Rs. 130,506 crore from Rs. 119,386 crore in 2017-18. By 2020, India is likely to be among top three pharmaceutical markets by incremental growth and 6th largest market globally in absolute size.

India's domestic pharmaceutical market turnover reached Rs. 119,386 crore in 2017-18, growing 5.7 % year-on-year from Rs. 111,135 crore in 2016-17. In India, medicine spending is projected to grow by 9 % - 12 % over the next five years, India to become leader in one of the top 10 countries in terms of medicine spending. India's cost of production is significantly lower than that of the US and almost half of that of Europe. It gives a competitive edge to India over competitor's counties. The Ayurveda sector in India is expected to reach US $ 4.4 billion by 2018 end and grow at 16 % CAGR till 2025. Increase in the size of middle class households coupled with the improvement in medical infrastructure and increase in the penetration of health insurance in the country will also influence in the growth of pharmaceuticals sector.

With 70 % of market share (in terms of revenues), generic drugs form the largest segment of the India pharmaceutical sector. Over the Counter (OTC) medicines and patented drugs constitute 21 % and 9 %, respectively. The share of generic drugs is expected to continue increasing; domestic generic drug market is expected to reach US $27.9 billion in 2020. Due to their competence in generic drugs, growth in this market offers a great opportunity for Indian firms. Based on moving annual turnover, Anti-Infective (13.4%), Cardiac (12.6%), Gastrointestinal (11.4%) had the biggest market share in the Indian pharma market in 2018-19. The highest growth in sales in 2018-19 were seen in Urology (16.4%), antiDiabetic (14.8%), and Cardiac (13.2%).

(Source: AIOCD-AWACS March 19)

C. Opportunities in Healthcare:

Public healthcare Infrastructure: There has been strong push by the Government to enhance the quality of accessible high quality healthcare infrastructure. 6 more AIIMS have been proposed Super specialty blocks in 70 Medical Colleges & expansion of inpatient provision at District level are being made.

(Source: National Health Policy 17-18)

Metro healthcare Significant Expansion of cancer & chronic care infrastructure across PHCs, CHCs & District Hospital are being made Improving Drug Procurement: Along with healthcare infrastructure the Government of India is also taking significant in improving drug accessibility to all sections of the Indian population. The Affordable Medicines & Reliable Implements for Treatment (AMRIT) scheme initiated to improve medical product accessibility for cancer and cardiovascular treatment is being expanded to all State Government Hospitals. The Jan-Aushadhi initiative aimed at making low cost generic medicines available has expanded to 3000 new outlets.

(Source: National Health Policy 17-18)

Clinical Trial Market: India is among the leaders in the clinical trial market. Due to a genetically diverse population and availability of skilled doctors, India has the potential to attract huge investments to its clinical trial market. Number of clinical trials in India increased by 400 % to 97 trials in 2017, compared with 13 trials approved in 2013.

(Source: PwC, McKinsey, Pharmaceuticals Promotion Council of India) High-end drug: Due to increasing population and income levels, demand for high-end drugs is expected to rise. Growing demand could open up the market for production of high-end drugs in India.

(Source: PwC, McKinsey, Pharmaceuticals Promotion Council of India)

Penetration in Rural Market: With 70 % of India's population residing in rural areas, pharma companies have immense opportunities to tap this market. Demand for generic medicines in rural markets has seen a sharp growth. Various companies are investing in the distribution network in rural areas.

(Source: PwC, McKinsey, Pharmaceuticals Promotion Council of India)

CRAMS: The Contract Research and Manufacturing Services industry (CRAMS) - estimated at US $ 17.27 billion in 2017-18, is expected to reach US $ 20 billion by 2020. The market has more than 1,000 players.

(Source: PwC, McKinsey, Pharmaceuticals Promotion Council of India)

D. Outlook & Risks and concerns:

For past three years, Indian Pharma Companies have been going through a tough phase due to significant competitive intensity and pricing pressure in the US and regulatory hurdles in India in terms of demonetisation, GST implementation and lower prices.

(Source: ETMarket - Outlook 2019)

Regulatory environment will continue to be unfavorable with Ban on Fixed Dose Combination & Pricing capping on essential drugs. Trade Generics gaining ground in Class III and IV towns. Small Propaganda Companies capturing regional shares. Increasing push for generics by the regulatory authorities.

(Source: AIOCD-AWACS SWOT of IPM Presentation)

Diagnostics Industry shows sluggish growth due to sever price competition & home-base diagnosis is increasingly important.

(Source: ET Market - Outlook 2019)

E. Financial performance and Operations review

During the year under review, your Company registered a standalone total income of Rs. 1,13,067.38 Lakhs as against Rs. 1,12,145.98 Lakhs in the previous year, thereby registering a growth of 0.83%.

The Earnings before Interest and Depreciation amounted to Rs. 27,483.97 Lakhs as against Rs. 27,034.83 Lakhs in the previous year. The Net Profit After Taxation stood at Rs. 17,153.63 Lakhs as against Rs. 16,831.41 Lakhs in the previous year.

During the year under review, your Company registered a consolidated total income of Rs. 113,416.59 Lakhs as against Rs. 113,405.02 Lakhs in the previous year, thereby registering a growth of 0.01 %.

F. Segment wise / Product wise performance

(i) Marketing:

In Therapy growth matrics, Cardiac, Anti-Diabetics, Neurological doing well with volume growth. Whereas Dermatological. Vitamins/ Minerals/ Nutritional & Anti Infective doing well with new product growth.

Acute remain the dominant therapy mainly driven by Value; whereas Chronic receives contribution from Volume as well. In last 5 year contribution of Anti Infective contribution reduce from 15 % to 13%. Where Anti Diabetics increase from 7 % to 9%. SGLT2 (Sodium Glucose Co-Transport-2) & Gliptins drive the Anti Diabetics growth & Telmisertan Combination & Sacubitril + Valsartan drive the growth of Cardiac therapy.

(Source: AIOCD-AWACS SWOT of IPM Presentation)

In FDC Ltd therapy growth metrics is doing well with new introduction in Ophthalmological & Dermatological. Dermatological & Pain / Analgesic doing well with volume growth 10.5 % & 35.9 % respectively. Dependency on Anti Infective is again increased. Maximum share gain with Gastro, Derma, Gynaec Therapy Areas. In 2018-19 Incremental value only from Anti Infective, GastroIntestinal, rest Therapy Areas steady or negative is a concern.

(Source: AIOCD-AWACS Mar 19)

(ii). Research and Development

The prime objective of the formulation R & D team at FDC is to develop quality products at affordable prices. A dedicated team of scientists is engaged in focused research for the development of diverse dosage forms. The team is continuously engaged and committed to develop and successfully introduce new products and newer technologies at the commercial scale. The new product development initiatives range from conventional orals to more complex and advanced dosage forms. For a sustainable future R & D efforts are have been steadily expanding the footprint of the organization across various key markets into ROW and regulated geographies of Europe and US.

The Research & Development (R & D) Centres located at Jogeshwari & Kandivali (Mumbai) are duly recognised by the Department of Science and Technology. Your Company carries out its various R & D activities in the following areas:

• Formulations

The R & D Formulation team at FDC comprises of dedicated scientists engaged in focused research for the development of finished dosage forms. The team has been designing strategies to develop quality products at affordable prices. The group is committed to develop and has successfully introduced products employing newer technologies at the commercial scale. Also in the foray and designing, challenging complex generics for the regulated markets of US. Exhibit batches of ophthalmic products have been manufactured for registration in the US and UK. Several ophthalmic and solid oral products are in various stages of development for the US and UK markets.

• Synthetics

The Research and development centers located at Kandivali (Mumbai) is engaged in process development of niche products, particularly in area of Ophthalmic, Antihypertensive, Antifungal, Ant diabetic , Antihistaminic, Bronchodilator and New Chemical entity (NCE). The work on life cycle management of existing drug Substances is also being carried out with the aim of Cost effectiveness, backward integration and meeting regulatory requirement from drug authorities, which enables to attain accreditation from various World Regulatory Authorities. The other highlights of the process developments of new molecules are Non infringing processes, Usage of environment friendly chemicals, Green chemistry, Development of desired polymorphs, Usage of classical chemistry for development of chiral drugs, and to minimise effluents etc.

• Nutraceuticals

During the year, your Company has launched the Enerzal 500 ml in pet bottle as well as 1 Litre in Tetrapak with Orange and Apple flavour. To extend the product categories of Infant Milk Substitute (IMS), the division is working on advanced range of Simyl MCT with some added micro nutrients like Nucleotides, Amino Acids and Omega3, O6 and also has developed MUM MUM 2 as a follow up formula with complete stability study & MUM MUM 3 which is under stability study. Trials and validation of IMS at Sinnar Plant is successfully completed, which completes the commissioning activity at Sinnar Plant. With this, we will be ready to supply current market requirement of IMS with spare capacity, which shall help us in launching new range of products under IMS and complimentary foods for infants.

• Biotechnology

a. G-CSF Project

Your company has received a test license (Test Licence No : 201515686 dated 19-06-18) under Form 29 for product Filgrastim. This licence is to manufacture the product for purpose of examination, test or analysis. For the manufacture of Filgrastim batches for purpose of clinical trial we have submitted the Audit Compliance report to DCGI office, New Delhi against the last CDSCO Audit observation. We hope to receive the NOC to manufacture Clinical Trial batches for product Filgrastim (G-CSF) in due course of time.

As a part of compliance to the CDSO audit observation we have implemented the Quality Management System in R & D Biotechnology Department to meet the cGMP requirement. Standard Operating Procedures for - Process activities, Analytical Testing & Quality Control, Equipment operations, Quality Assurance and Miscellaneous activities have been prepared and made effective. All the Equipments have been shifted from the fifth floor facility to the new Bioprocess and Bioanalytical lab on ground floor and these have been installed and qualified accordingly. Area Qualification activity of R & D Bioprocess Area has been completed successfully. The new water system installed in the bioprocess area was subjected to validation and Phase I / Phase II validation activity for the same is completed whereas Phase III validation activity is underway.

b. Third Generation Thrombolyte Project

The external party M/s Premas has been successful in developing a refolding and purification strategy to provide purified product. The trials for the upstream processing have efficiently been executed at lab scale at our Bioprocess facility and are found to be effective. We have successfully taken fermentation trials (10L capacity) and downstream processing trial (lab scale) for Reteplase molecule in our Bioprocess facility.

We are in process of initiating the technology transfer of the developed downstream process. Furthermore standardization and validation studies will be conducted on the developed process before finalization.

c. Conversion of Non-sterile to sterile API (Lab scale):

Brinzolamide API was successfully sterilized In-house (Lab-scale) using strict aseptic techniques as per the synthesis process provided by R & D Synthesis lab. The above Brinzolamide samples were then subjected to Sterility testing by Corporate Microbiology and complete testing by R & D Synthesis lab. The sterility test result of sample complies with the test and the product meets the specifications of Brinzolamide API except the particle size.

For further aseptic process scale up and particle size reduction we need to procure equipment's suiting our requirement and meeting GMP norms.

d. Microbial Testing Lab

R & D Microbial Testing lab (MTL) is working in collaboration with R & D Organic Synthesis lab for development of new salt forms (Sodium, Potassium, acid, tetrazoles, Dimethylamine etc) of the existing NCE molecules with better water solubility and synthesizing higher quantities of the shortlisted molecules for further studies.

R & D MTL lab has performed primary screening of more than 90 molecules for their water solubility and antifungal activity. Three new molecules showing promising antifungal activity have been shortlisted and synthesized in higher quantities for testing. These molecules have been sent to external party for Animal toxicity studies. Based on the outcome of this study we plan to initiate preformulation work and future strategy for these NCE's.

(iii). Exports

Your Company's Annual Export turnover of Active Pharmaceutical Ingredients (API) and Finished Formulations for the financial year ending March 31,2019 was Rs. 17,118.15 Lakhs as compared to Rs. 13,269.26 Lakhs in the last financial year 2017-18. The API business has registered Sales of Rs. 5,108.21 Lakhs in the current financial year. Your Company has filed new USDMF for Dorzolamide Hydrochloride USP (Process II). For Europe region, we have received Certificate of Suitability (CEP) Certification for API Fluconazole. We have also received approval for Olopatadine Hydrochloride from the New Zealand Health agency (MEDSAFE).

The Roha Plant was successfully audited by USFDA with no any 483 observations. Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (cGMP).

API Cinnarizine EP Drug Master File (DMF) has been submitted to Russian Agency. About 10 submissions for 3 APIs have been made to ROW markets. Existing 4 APIs DMFs were resubmitted in e-CTD format as a complete DMF, to Health Agencies.

On the finished dosage forms side, USA and UK markets continued to be the major contributors to the export turnover with sales of Rs. 2,954.86 Lakhs and Rs. 1,163.68 Lakhs respectively despite continued headwinds & pressure on pricing in the US Generics business from supply chain consolidation.

The Company's product portfolios of Ophthalmics and Oral Rehydration Salts drove export sales in FY19. Finished Formulations of the Company are now exported to about 33 countries.

The company received the Abbreviated New Drug Application (ANDA) Approval for Dorzolamide 2% Ophthalmic Solution 5 ml & 10 ml this year. The company plans to launch this product in the US market in the 3rd Quarter of financial year 2019-20 through its strategic marketing partner.

The company continues to export its Anti-Diarrheal product range to reputed global NGOs like UNICEF- Denmark & MSF-France/Belgium, thus maintaining its reputation of being one of their preferred suppliers for emergency supplies worldwide.

The company continues to work on filing additional ANDAs in the US market to support the existing basket of ophthalmic products to pursue its growth objectives in the Regulated markets. In the less Regulated markets, the Company is associated with leading regional companies in Asia, Africa, Latin America, CIS, and Middle East to expand its branded formulations business and continue efforts to open new markets for its range of formulations as well as APIs.

FDC International Ltd - UK, the 100% Subsidiary of FDC Limited-India registered a sales turnover of GBP 18.44 Lakhs by selling its products in the United Kingdom and the Netherlands.

G. Internal Financial Controls and their adequacy

Your Company has in place a robust Internal Financial Control commensurate with the size, scale and complexity of its operations. These controls ensure that the transactions are recorded and reported diligently, adhere to the Company's policies & systems, safeguard the assets, prevent and detect the frauds and errors, accuracy and completeness of the accounting records and timely preparation of reliable financial information.

Your Company has an internal audit department which carries out audits throughout the year and appropriate actions are taken by the management based on their recommendations.

H. Human Resources

Your Company believes that the employees are the most valuable assets and key drivers of business success and sustained growth. The Company believes in quality process, systems and compliance. Our Human Resource policies and practices are well aligned to meet our business objectives.

Your Company operates in a highly competitive environment. The Human resources attracts and retains the best talent for its operations across all locations. The company encourages and provides the platform to the individual to excel in their professional and personal goals along with the focus on a healthy work life balance. Your Company has in place a variety of initiatives to engage its employees including fitness programme.

Being future ready is one of the key processes for sustainable growth and Company is building synergy and cultural integration through coherent Leadership program for top leaders as a part of its core initiative. The Company has in-house Training and Development to help the sales team on products, scientific knowledge, selling techniques. Company has also conducted various programs on Managerial effectiveness to improve the individual competencies and leadership abilities for sales leadership. Your Company understands the importance of newer training technique and would be migrating from class room training to an e-learning platform for its sales team in the next financial year. The web based training will provide self paced learning through interactive ways.

In line with the requirement of SEBI listing regulations, your company has adopted a "Code of Conduct and work ethics policy and Whistle Blower Policy". The policy on Whistle Blower are uploaded on the company's website.

i.e. www.fdcindia.com

I. Cautionary Statement

Certain statements in respect to Management Discussion and Analysis Report may be forward looking and are stated as required by the applicable laws and regulations. The future results of the Company may be affected by many factors, which could be different from what the Directors envisage in the terms of future performance and outlook.

6. MATERIAL CHANGES AND COMMITMENTS AFTER THE END OF THE FINANCIAL YEAR

No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year to which financial statements in this report relates and the date of this report.

7. AUDITORS REPORT

The Report given by B S R and Co LLP Statutory Auditors on the Financial Statements of the Company for the year ended March 31, 2019 is a part of the Annual Report. There has been no qualification, reservation or adverse remark or disclaimer in the said audit Report.

8. CONSOLIDATED FINANCIAL STATEMENTS

The Consolidated Financial Statements of the Company form part of this Annual Report. These statements have been prepared on the basis of Audited Financial Statements received from the subsidiary companies as approved by their respective Board of Directors.

9. SUBSIDIARIES / JOINT VENTURE AND ITS OPERATIONS

Your Company has 2 (Two) wholly owned Subsidiaries namely FDC Inc., USA and FDC International Ltd, UK and 1 (One) Joint Venture business, namely Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. at South Africa. The Financials of the Subsidiaries and Joint Venture Company are disclosed in the Consolidated Financial Statements, which forms a part of this Annual Report.

A statement containing salient features of the Financial Statements of Subsidiary Companies/ Joint Ventures is annexed to this Report as "Annexure B" pursuant to the provisions of Section 129 of the Companies Act, 2013 and the Rules made thereunder in the prescribed Form No. AOC-1 and hence, the same is not repeated for the sake of brevity.

In accordance with the provisions of Section 136 (1) of the Companies Act, 2013, the following information has been uploaded on the website of the Company i.e. www.fdcindia.com :

(a) Annual Report of the Company, containing therein its Standalone and the Consolidated Financial Statement; and

(b) Audited Annual Accounts of each of the Subsidiary companies and Joint venture.

10. BUSINESS RESPONSIBILITY REPORT

As per Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Business Responsibility Report is annexed as "Annexure C".

11. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(3) (c) of the Companies Act, 2013, your Directors state that:

(a) In the preparation of Annual Accounts for the year ended March 31, 2019, the applicable Accounting Standards have been followed along with proper explanations relating to material departures, if any;

(b) They have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2019 and of the profit of the Company for the year ended on that date;

(c) They have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

(d) They have prepared the Annual Accounts on a going concern basis;

(e) They have laid down proper Internal Financial Controls to be followed by the Company and they were adequate and operating effectively; and

(f) They have devised proper systems to ensure compliance with the provisions of all applicable laws and such systems were adequate and operating effectively.

12. PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS

Details of Loans, Guarantees and Investments made by the Company are given in the notes to the Financial Statements.

Your Company has not given any Loans or Guarantees or Investments in contravention of the provisions of Section 186 of the Companies Act, 2013.

13. PUBLIC DEPOSITS

During the year under review, your Company has not accepted any deposits from the Public and as such no amount of principal or interest on deposits from Public was outstanding as on the date of the Balance Sheet.

14. ENERGY CONSERVATION, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

The information relating to energy conservation, technology absorption, foreign exchange earnings and outgo, pursuant to Section 134 of the Companies Act, 2013 and the Rules made thereunder, is annexed as "Annexure D" to this Report.

15. DIRECTORS AND KEY MANAGERIAL PERSONNEL Resignation of Directors:

Pursuant to the SEBI (Listing Obligations & Disclosure Requirements) (Amendment) Regulation, 2018, Dr. Rahim Muljiani, Dr. Satish Ugrankar and CA. Vinod Yennemadi, Independent Directors of the Company, ceased to be Directors of the Company with effect from April 01, 2019. The Board placed on record its deep appreciation for contributions on key issues. Further the Board has confirmed that there were no other reasons attributable or connected with the Company.

Appointment of Chairman of the Board:

Mr. Mohan A. Chandavarkar stepped down from the position of Chairman of the Board and CA. Uday Kumar Gurkar was appointed as Chairman of the Board w.e.f. April 01,2019.

Appointment of Directors:

Upon recommendation of Nomination and Remuneration Committee, Mr. Melarkode Ganesan Parameswaran (DIN: 00792123), Ms. Usha Athreya Chandrasekhar (DIN: 06517876), and Dr. Mahesh Bijlani (DIN: 0008447258) were appointed by the Board of Directors as an Additional Non-Executive Independent

Director of the Company for a consecutive period of 5 (five) years w.e.f. May 10, 2019 subject to approval of the shareholders at the ensuing Annual General Meeting.

Above Independent Directors were appointed as an Independent Director ("ID") on May 10, 2019 upto the conclusion of Seventy Ninth Annual General Meeting in the calendar year 2019. Based on the recommendation of Nomination and Remuneration Committee, the Board of Directors at their meeting held on May 24, 2019 approved their appointment as an ID of the Company, subject to approval of the shareholders at ensuing Annual General Meeting.

All Independent Directors have given declarations that they meet the criteria of independence as laid down under Section 149(6) of the Companies Act, 2013 and Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Based on disclosures provided by Directors, none of them are disqualified from being appointed as Directors under Section 164 of the Companies Act, 2013.

Retirement by rotation:

In accordance with provisions of the Companies Act, 2013 and the Articles of Association of the Company, Ms. Nomita R. Chandavarkar, Whole time Director, retires by rotation at the 79th Annual General Meeting and being eligible, has offered herself for re-appointment. The Profile of Director seeking reappointment pursuant to Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is included in the Notice of the 79th Annual General Meeting and the statement annexed thereto.

Re-appointment of Directors:

The Board of Directors on recommendation of the Nomination and Remuneration Committee, have approved re-appointment of :

1. Mr. Nandan M. Chandavarkar as a Joint Managing Director of the Company for a period of five years with effect from March 01,2019, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

2. Ms. Nomita R. Chandavarkar as an Executive Director, for a period of 5 (five) years with effect from June 02, 2019, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

3. Mrs. Swati S. Mayekar as an Independent Director, for the second term for a period of 5 (five) years with effect from September 06, 2019, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

4. Mr. Ameya A. Chandavarkar as an Executive Director of the Company, designated as Chief Executive Officer (CEO) - International Business - Executive Director for a period of 5 (five) years w.e.f. November 01,2019, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

Profile of Directors seeking appointment / re-appointment:

As required under regulation 36(3) of the Listing Regulations, particulars of Directors seeking appointment / re-appointment at the ensuing Annual General Meeting are annexed to the notice convening Seventy Ninth Annual General Meeting.

Key Managerial Personnel:

In terms of Section 203 of the Act, the following are the Key Managerial Personnel (KMP) of the Company as on March 31,2019 :

1. Mr. Mohan A. Chandavarkar, Managing Director *

2. Mr. Sanjay B. Jain, Chief Financial Officer

3. Ms. Varsharani Katre, Company Secretary

During the year, no KMP has been appointed or has retired or resigned.

* With effect from April 01, 2019 Mr. Mohan A. Chandavarkar has ceased to be the Chairman of the Company.

16. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES

Information pursuant to Rule 5(1), (2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed to this report as "Annexure E".

17. CORPORATE GOVERNANCE

In terms of Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Report on Corporate Governance along with a Compliance Certificate issued by the Statutory Auditors of the Company, forms part of the Annual Report.

18. RISK MANAGEMENT

The Risk Management Committee identifies and evaluates the business risks, in addition to overseeing the Risk Management Policy of the Company, from time to time. The details of the Risk Management Committee are included in the Corporate Governance Report.

19. NOMINATION AND REMUNERATION POLICY

Your Company has in place, a Nomination and Remuneration Policy for selection, appointment and remuneration of Directors, Key Managerial Personnel and Senior Management Team. The details of this Policy are provided in the Corporate Governance Report.

20. MEETINGS OF THE BOARD AND COMMITTEES THEREOF

The information has been furnished in the Corporate Governance Report.

21. AUDIT COMMITTEE

The Audit committee reviews all the information that is required to be mandatorily reviewed by it under the Corporate Governance and other matters as per terms of reference to Audit Committee, inter-alia, covers all the matters specified under Section 177 of the Companies Act, 2013 and also all the matters listed under Part C of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Audit Committee of the Board as on March 31,2019 comprises of 4 (Four) Non-Executive Independent Directors and 1 (One) Executive Director. CA. Swati S. Mayekar is the Chairperson of the Committee. Dr. Rahim H. Muljiani, CA. Vinod G. Yennemadi, CA. Uday Kumar Gurkar and Mr. Mohan A. Chandavarkar are the other members of the committee. The Company Secretary acts as the Secretary to the Committee. The CFO is the permanent invitee to the Committee meeting. The Internal Auditor and the concerned partners/ authorised representatives of Statutory Auditors are regular invitees of the Committee meetings.

However with effect from May 10, 2019 Composition of Audit Committee has been changed, Dr. Rahim Muljiani and CA. Vinod Yennemadi ceased to be member of Audit Committee pursuant to their resignations from the Board.

The Powers and Role of the Audit Committee are provided in the Corporate Governance Report. All recommendations made by the Audit Committee were accepted by the Board of Directors.

22. BOARD & DIRECTORS EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has carried out the Annual Performance, Evaluation of its own performance, the Directors individually as well as the evaluation of the working of its Audit, Nomination and Remuneration and Compliance Committees, based on the evaluation parameters formulated by the Nomination and Remuneration Committee. The manner in which the evaluation was carried out has been explained in the Corporate Governance Report.

23. FAMILIARISATION PROGRAMME FOR INDEPENDENT DIRECTORS

The Independent Directors are familiarized with their roles, rights, responsibilities of the Company, the business model of the Company, etc., through various programmes on a continuous basis. Details of the familiarization program of independent directors are disclosed on the website of the Company.

i.e.http://www.fdcindia.com/admin/images/Familiarisatio n_Programme_2018-19.pdf

24. VIGIL MECHANISM/ WHISTLE BLOWER POLICY

Your Company has in place a Whistle Blower Policy for reporting genuine concerns or grievances on fraud and mismanagement. The said Policy is explained in detail in the Corporate Governance Report.

The Company has not denied any person from accessing the Audit Committee. There were no allegations/ disclosures/ concerns received during the year under review, in terms of the vigil mechanism established by the Company. The said Policy is also uploaded on the website of the Company i.e.http://www.fdcindia.com/admin/ images/Whistler_ Blower_Policy.pdf

25. CODE OF CONDUCT

Your Company has in place a Code of Conduct for Board Members and Senior Management Personnel of the Company. The Code of Conduct lays down the standard of conduct which is expected to be followed by the Directors and the Senior Management Personnel and the duties of Independent Directors towards the Company.

The Directors and Senior Management Personnel have affirmed compliance with the Code of Conduct applicable to them, during the year ended March 31, 2019. A Certificate duly signed by the Managing Director, on the compliance with the Code of Conduct is given in the Corporate Governance Report. The said Code is available on the website of the company i.e. http://www.fdcindia.com/admin/images/Code_of_ Conduct_of_FDC_Limited.pdf

26. PREVENTION OF INSIDER TRADING

Your Company has in place a Policy on the Code of Conduct for Prevention of Insider Trading with a view to regulate the trading in securities by the Promoters, Directors and the Designated Employees of the Company.

The same has also been uploaded on the website of the Company i.e. http://www.fdcindia.com/admin/images/ Code_of_Conduct_For_Prevention_of_Insider_Trading.pdf

The Promoters, Directors and the Designated Employees have affirmed compliance with the Company's Code of Conduct for Prevention of Insider Trading.

27. RELATED PARTY TRANSACTIONS

During the year under review, all Related Party Transactions entered into by the Company were on an arm's length basis and in the ordinary course of business. Your Company has not entered into any contract, arrangement or transaction with any Related Party which would be considered as the material under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board has also approved a policy on Related Party Transactions and the same has been uploaded on the Website of the Company i.e. http://www.fdcindia.com/ admin/images/Policy_on_Related_Party_Transactions. pdf

A statement giving details of all Related Party Transactions is placed before the Audit Committee and the Board of Directors on a quarterly basis. Omnibus prior approval was also obtained from the Audit Committee and the Board on an annual basis for repetitive transactions.

Related Party Transactions as required under Accounting Standard are reported in the notes to financial statement The particulars as required under Section 134(3)(h) of the Companies Act, 2013 are furnished as "Annexure - F" to this report.

28. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN OF WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place a Policy on the Prevention, Prohibition and Redressal of Sexual harassment at workplace in line with the requirements of The Sexual Harassment of Women of Workplace (Prevention, Prohibition and Redressal) Act, 2013.

The said Policy is available on the website of the Company i.e. http://www.fdcindia.com

33. TRANSFER OF UNPAID AND UNCLAIMED DIVIDEND AMOUNTS AND SHARES TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

a. Pursuant to the provisions of the Companies Act, 2013, read with IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended, declared dividends which remained unpaid or unclaimed for a period of 7 (Seven) years have been transferred by the Company to the IEPF, which has been established by the Central Government.

Your Company has been sending reminders to those Members having unpaid/unclaimed dividends before transfer of such dividend(s) to IEPF. Details of the unpaid/unclaimed dividend are also uploaded on the Company's website i.e. www.fdcindia.com .

Members, who have not encashed their dividend pertaining to Final Dividend 2011-2012 and onwards, are advised to write to the Company immediately for claiming dividends declared by the Company.

b. In view thereof, after complying with the prescribed procedure, 47,714 shares on which dividend remained unclaimed for 7 (Seven) consecutive years, were transferred to IEPF account in the year 2018. Your Company has uploaded the details of such Shareholders whose shares are transferred to IEPF account on the website of the Company i.e. www.fdcindia.com . The procedure to claim the shares transferred to IEPF account has also been uploaded on the website.

34. ENVIRONMENT, HEALTH AND SAFETY

Environment, Health and Safety are a part of the Management responsibilities and concerns. Your Company has been providing various kinds of medical assistance to the families of its employees. Periodic health checkups are also carried out for all the employees. Employees are also educated on safety and precautionary measures to be undertaken on their job.

35. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS

There are no significant or material orders passed by any regulatory, tribunal or court that would impact the going concern status of the Company and its future operations.

36. ACKNOWLEDGEMENTS

Your Directors would like to express and place on record their sincere appreciation for the continued co-operation and support received from the Medical fraternity, Government Authorities and Agencies, Stock Exchanges, Financial Institutions, Investors, Bankers, Consumers, Vendors and Members, during the year under review. Your Directors also place on record their appreciation for the hard work and contribution of all the employees of the Company.

For and on behalf of the Board

Place : Mumbai CA. UDAY KUMAR GURKAR
Date : May 24, 2019 Chairman of the Board

   

FDC Ltd Company Background

Uday Kumar GurkarMohan A Chandavarkar
Incorporation Year1940
Registered OfficeB-8 MIDC Industrial Area,Waluj Dist
Aurangabad (Maharashtra),Maharashtra-431136
Telephone91-240-2554407/967/299,Managing Director
Fax91-240-2554299
Company SecretaryVarsharani Katre
AuditorB S R & Co LLP
Face Value1
Market Lot1
ListingBSE,MSEI ,NSE,
RegistrarSharex Dynamic (India) Pvt Ltd
Unit No 1 Luthra Ind,Andheri Kurla Road ,Safed Pool Andheri(E,Mumbai - 400 072

FDC Ltd Company Management

Director NameDirector DesignationYear
Mohan A Chandavarkar Managing Director 2021
Ashok A Chandavarkar Director 2021
Nandan M Chandavarkar Joint Managing Director 2021
Ameya A Chandavarkar Director 2021
Ramdas A Chandavarkar Chairman Emeritus 2021
Varsharani Katre Company Secretary 2021
Nomita R Chandavarkar Director 2021
Swati S Mayekar Independent Director 2021
Uday Kumar Gurkar Chairman 2021
MELARKODE GANESAN PARAMESWARAN Independent Director 2021
Usha Athreya Chandrasekhar Independent Director 2021
Mahesh Bijlani Independent Director 2021

FDC Ltd Listing Information

Listing Information
BSE_500
BSE_HC
CNX500
BSESMALLCA
CNXSMALLCA
BSEALLCAP
SML250
MSL400
NFTYMSC400
NFTYSC250
NF500M5025

FDC Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Sales NA 0001322.6448
Export Incentives NA 0006.772
Other Operating Income NA 0001.6762
Others NA 0000
Foods NA 0000
Basic Drugs Kg 0000
Bulk Drugs NA 0000
Capsules No 0000
Capsules - Food Products No 0000
Creams/Powder/Ointment/GranuleKg 0000
Injectables-Ophthalmics Ltr0000
Powder - Food Products Kg 0000
Tablets No 0000
Formulations NA 0000

Contact us Contact us